Amylyx Pharmaceuticals Inc (AMLX)vsEli Lilly and Company (LLY)
AMLX
Amylyx Pharmaceuticals Inc
$23.35
-1.18%
HEALTHCARE · Cap: $2.26B
LLY
Eli Lilly and Company
$1,220.42
+0.43%
HEALTHCARE · Cap: $1.02T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates -10864611% more annual revenue ($72.25B vs $-665,000). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
AMLX
Avoid33
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Trading at 9.5x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 34.9x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : AMLX
The primary concerns for AMLX are Price/Book, EPS Growth, Profit Margin.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, P/E Ratio, Debt/Equity. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMLX profiles as a value stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.51 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 33/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?